🇺🇸 FDA
Patent

US 7618632

Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 7618632 (Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/505, A61K38/00, A61P, A61P1/04